Comparative Pharmacology
Head-to-head clinical analysis: BACITRACIN ZINC NEOMYCIN SULFATE POLYMYXIN B SULFATE versus GENOSYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACITRACIN ZINC NEOMYCIN SULFATE POLYMYXIN B SULFATE versus GENOSYL.
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE vs GENOSYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bacitracin zinc inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier that transports peptidoglycan precursors. Neomycin sulfate and polymyxin B sulfate are aminoglycoside and polypeptide antibiotics, respectively; neomycin binds to 30S ribosomal subunit and causes misreading of mRNA, while polymyxin B disrupts bacterial cell membrane permeability by interacting with phospholipids.
Genosyl (sodium phenylbutyrate) is a prodrug that is metabolized to phenylacetate, which conjugates with glutamine via acetylation to form phenylacetylglutamine. This alternative pathway facilitates waste nitrogen excretion in patients with urea cycle disorders.
Apply topically (ointment or cream) to affected area 1-3 times daily. For ophthalmic use, instill 1-2 drops into affected eye(s) every 3-4 hours.
5 mg orally once daily for 14 days, then 2.5 mg orally once daily thereafter.
None Documented
None Documented
Neomycin: 2-3 h; polymyxin B: 4.5-6 h; bacitracin: 1.5 h. Combined: effectively ~2-6 h depending on renal function; clinical context: prolonged with renal impairment.
Terminal half-life 3.5 hours; clinically relevant for dosing every 6-8 hours in renal impairment.
Neomycin: ~99% renal; polymyxin B: ~60% renal, 40% fecal; bacitracin: mainly renal (over 90%). Combined: renal (predominant), with minor biliary/fecal contribution (polymyxin B).
Renal: 85% unchanged; biliary/fecal: 15% as metabolites.
Category A/B
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic